TM
SUPN icon

Torren Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Torren Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558 Hold
12
– – ﹤0.01% 851
2026
Q1 		$620 Sell
12
-974
-99% -$49.6K ﹤0.01% 843
2025
Q4 		$49K Buy
+986
New +$47.9K 0.03% 324

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Torren Management's SUPN Position: Q2 2026 in Review

Torren Management held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 12 shares worth $558. The position accounts for ﹤0.01% of the portfolio, ranked #851.

Torren Management first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $49K in Q4 2025. 131 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Torren Management held 12 shares of Supernus Pharmaceuticals worth $558 as of Q2 2026.
  • Torren Management left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #851 holding.
  • Torren Management first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Supernus Pharmaceuticals position peaked at $49K in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.